Peer-reviewed article
Pediatric Tuberculosis: Unraveling Immunity, Clinical Complexities, and Resource-Driven Disparities in the Pursuit of Prevention.
Daniel Mashiach, Justin Shon, Raquel Mashiach, Gregory Ayzenberg, Osnat Barazani et al. ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This review examines pediatric tuberculosis as a major but underrecognized cause of childhood death and illness, especially in low-resource settings. It explains why young children are particularly vulnerable to severe TB, including immune immaturity and malnutrition, and describes the clinical challenges in diagnosis and treatment. The review emphasizes that BCG vaccination remains important for preventing severe disease, but effectiveness varies by setting, and that equitable access to vaccines and preventive therapy is essential to reduce pediatric TB deaths globally.
Key points
- Pediatric TB mortality is disproportionately high despite children representing a minority of TB cases, particularly in children under five years old
- Children with HIV, malnutrition, type 1 diabetes, or immunosuppression are at heightened risk for severe disease
- Delayed diagnosis, inadequate linkage to care, and limited treatment access are major drivers of poor outcomes in low-resource settings
- BCG vaccination effectiveness in preventing severe disease and death is context-dependent and varies by region
- Multidrug-resistant TB in children is rising, particularly in regions with low sociodemographic development
Limitations
This is a narrative review synthesizing existing knowledge rather than a primary research study, so it cannot provide new empirical evidence on the effectiveness of specific interventions. The document does not report quantitative outcome data from intervention trials.
Abstract
Pediatric tuberculosis (TB) remains a critically underrecognized contributor to global childhood morbidity and mortality, with the highest burden concentrated in low-resource settings. Although children comprise a minority of overall TB cases, mortality is disproportionately high, particularly among those under five years of age, driven largely by delayed diagnosis, inadequate linkage to care, and limited access to effective treatment. The continued rise of pediatric multidrug-resistant TB (MDR-TB), especially in regions with low sociodemographic development, further highlights persistent gaps in current control strategies. This review synthesizes key aspects of pediatric TB pathogenesis and host immune responses that predispose young children to rapid disease progression and severe outcomes, including immune immaturity and paucibacillary infection. We summarize pulmonary and extrapulmonary disease manifestations and identify populations at heightened risk, including children with HIV, malnutrition, type 1 diabetes mellitus, and congenital or treatment-related immunosuppression. Ongoing challenges in diagnosis and treatment are discussed, including limitations of existing microbiologic and immunologic tests, specimen collection constraints, regimen toxicity, and barriers to adherence. Prevention remains central to reducing pediatric TB mortality. We highlight the sustained importance of bacille Calmette-Guérin (BCG) vaccination in preventing severe disease and death, the context-dependent variability in vaccine effectiveness, and the structural and socioeconomic determinants of vaccine coverage. We conclude that integrating equitable vaccine delivery, scalable preventive therapy, and child-adapted diagnostic strategies is essential to meaningfully reduce the global pediatric TB burden.